Search

Displaying results 2411 - 2420 of 4234 in total
  1. Drug

    NGD-4715

    go.drugbank.com/drugs/DB06027
    Experimental

    NGD-4715 functions as a melanin-concentrating hormone receptor 1 antagonist.

  2. Drug

    4-Hydroxytestosterone

    go.drugbank.com/drugs/DB01485
    IllicitInvestigational

    Formestane (Lentaron) acts as a prohormone of 4-Hydroxytestosterone, as 4-Hydroxytestosterone is one of the many byproducts of formestane metabolism.

  3. Drug

    Tyrosine

    go.drugbank.com/drugs/DB00135
    ApprovedInvestigationalNutraceutical

    Tyrosine is a non-essential amino acid. In animals it is synthesized from phenylalanine. It is also the precursor of epinephrine, thyroid hormones, and melanin.

  4. Drug

    Etacrynic acid

    go.drugbank.com/drugs/DB00903
    ApprovedInvestigational

    This compound has been classified as a loop or high ceiling diuretic.

  5. Drug

    Almitrine

    go.drugbank.com/drugs/DB01430
    Approved

    Almitrine is a respiratory stimulant that enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies.

  6. Drug

    Levallorphan

    go.drugbank.com/drugs/DB00504
    Approved

    It should be used cautiously; levallorphan reverses severe opioid-induced respiratory depression but may exacerbate respiratory depression such as that induced by alcohol or other non-opioid central depressants

  7. Drug

    Isometheptene

    go.drugbank.com/drugs/DB06706
    Approved

    Isometheptene is a sympathomimetic drug that causes vasoconstriction. It is used for treating migraines and tension headaches.

  8. Drug

    Lenvatinib

    go.drugbank.com/drugs/DB09078
    ApprovedInvestigational

    These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as … However, for patients with RAI-refractory thyroid cancer, treatment options are limited and the prognosis is poor, leading to a push for the development of more targeted therapies such as lenvatinib.

  9. Drug

    Pegloxenatide

    go.drugbank.com/drugs/DB19230
    Investigational

    Pegloxenatide is under investigation in clinical trial NCT05172999 (Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia).

  10. Drug

    Ecabet

    go.drugbank.com/drugs/DB05265
    Investigational

    Ecabet is currently marketed in Japan as an oral agent for treatment of gastric ulcers and gastritis.